An economic evaluation of combination treatment with budesonide and formoterol in patients with mild-to-moderate persistent asthma  by Jönsson, Bengt et al.
An economic evaluation of combination treatment
with budesonide and formoterol in patients with
mild-to-moderate persistent asthma
Bengt J .onssona,*, Fredrik Berggrenb, Klas Svenssonc, Paul M. O’Byrned
aCentre for Health Economics, Stockholm School of Economics, Box 6501 Stockholm 11383, Sweden
bLund University Centre for Health Economics, Lund, Sweden
cAstraZeneca R&D Lund, Lund, Sweden
dDepartment of Medicine, McMaster University, Hamilton, Ont., Canada
Received 27 March 2003; accepted 5 April 2004
Summary Patients with mild asthma may benefit from increasing their inhaled
corticosteroid dose, adding a long-acting b2-agonist, or both. This study assessed the
cost–effectiveness of these options. Patients agedX12 years with mild-to-moderate
persistent asthma (n¼ 1272) were randomised to twice-daily, double-blind treat-
ment with budesonide 100 mg, budesonide 100 mg plus formoterol 4.5 mg, budesonide
200 mg, or budesonide 200 mg plus formoterol 4.5 mg for 12 months. Clinical variables
included lung function, number of symptom-free days and number of severe
exacerbations. Data on medication use, hospitalisation, visits to health professionals
and time off work due to asthma were combined with Swedish unit cost data (1999)
to estimate the mean annual cost per patient. Budesonide 200 mg plus formoterol
4.5 mg had the greatest efficacy and effectiveness. Budesonide 200 mg plus
formoterol 4.5 mg was both more effective and less costly than budesonide 100 mg
plus formoterol 4.5 mg, so a cost–effectiveness ratio was not calculated for this
comparison. The cost–effectiveness ratio for budesonide 200 mg plus formoterol
4.5 mg compared with budesonide 200 mg alone was SEK 21 per symptom-free days
gained. The combination of budesonide and formoterol in mild-to-moderate
persistent asthma improved effectiveness at modest additional cost.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Asthma can be categorised as mild intermittent or
mild, moderate, and severe persistent, depending
on the severity, frequency and persistence of
symptoms and the level of medication required.1
The majority of patients treated in primary care
have mild intermittent or mild persistent asth-
ma.2,3 However, even patients with mild asthma
can be substantially affected by the disease and are
at risk from severe exacerbations.1,4
In addition to the impact on patients, the cost of
asthma is correspondingly high. For example, the
annual healthcare costs (direct costs) for asthma
treatment were calculated at SEK 1.1 billion in
Sweden in 1991 5 and US$ 7.4 billion in the USA in
1998.6 Productivity or indirect costs (the effect of
time lost from work and/or home-making) were
also substantial, taking the total costs to SEK 3.0
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Inhaled corticosteroids can improve asthma control
even in mild asthma,7,8 and in Sweden it has been
found that regions with high use of inhaled corticos-
teroids also have low rates of asthma hospitalisa-
tion.9 International guidelines recommend inhaled
corticosteroids for first-line use in mild persistent
asthma.1 For patients not optimally controlled by
low-dose inhaled corticosteroids alone, an additional
controller therapy, such as a long-acting b2-agonist,
or increased corticosteroid dose is recommended.1
In patients with moderate-to-severe asthma, the
risk of asthma exacerbations can be further
reduced by adding a long-acting b2-agonist, such
as formoterol, to inhaled corticosteroid treat-
ment.10 An economic evaluation using data from
this trial found that adding formoterol to an inhaled
corticosteroid treatment produced savings in
healthcare costs, which partly or completely offset
the additional costs of formoterol.11
The Oxiss (formoterol) and Pulmicorts (budeso-
nide) Turbuhalers In the Management of Asthma
(OPTIMA) clinical trial investigated whether the
results in moderate asthma could be extended to
patients with milder disease.3 The clinical analysis
examined the effects of adding formoterol to
inhaled corticosteroid treatment on the risk of
severe exacerbations, asthma symptoms, and lung
function. The study included two groups of
patients; Group A patients were not receiving
corticosteroids prior to the trial, and Group B
patients were receiving up to 400 mg per day of
inhaled budesonide or its equivalent.
Treatment regimens for mild persistent asthma
may raise concerns over costs, because of the large
numbers of patients involved. Therefore, a parti-
cular need exists for economic evaluation of
treatment regimens in mild asthma. In the OPTIMA
study, the Group B patients had mild-to-moderate
persistent asthma that was not optimally controlled
on budesonide 100 mg twice daily (Group B), and
were randomised either to continue on the same
dose or to receive one of three step-up treatments;
doubling the dose of budesonide; addition of
formoterol 4.5 mg; or both. Resource utilisation
data were collected alongside the clinical trial, and
this paper presents the results of an economic
analysis of the three step-up treatments.
Methods
Study design
The OPTIMA clinical study has been fully published
elsewhere.3 In brief, OPTIMA was a randomised,
prospective, double-blind, multicentre, parallel-
group trial conducted in 17 countries (Brazil,
Canada, Czech Republic, Denmark, Finland, Hun-
gary, Iceland, Italy, Mexico, The Netherlands, New
Zealand, Norway, Poland, Portugal, Spain, Sweden
and Taiwan) in patients aged at least 12 years.
Patients enrolled in Group B had been taking up to
400 mg per day of inhaled budesonide or its
equivalent for at least 3 months, and had a forced
expiratory volume in 1 s (FEV1) of X70% predicted
normal. After a 4-week run-in on budesonide 100 mg
twice daily, eligible patients were randomised to
twice-daily treatment for 1 year with either
budesonide 100 mg, budesonide 100 mg plus formo-
terol 4.5 mg, budesonide 200 mg, or budesonide
200 mg plus formoterol 4.5 mg, all delivered by
Turbuhaler. The budesonide dose is expressed as
the metered dose and the formoterol dose as the
delivered dose. Terbutaline (Bricanyls Turbuhaler)
was available as reliever medication throughout
the study.
The primary efficacy measures in the clinical trial
were the time to first severe exacerbation (defined
as hospital admission or emergency treatment for
worsening asthma; oral corticosteroid course;
425% decrease in morning peak expiratory flow
(PEF) from baseline) and the percentage of days
with poorly controlled asthma (defined as days with
morning PEF of at least 20% below baseline, where
more than two additional reliever medication
inhalations were needed, or with awakening due
to nocturnal asthma). Secondary efficacy measures
included: lung function; percentage of days with
symptoms; number of reliever inhalations required;
percentage of nights with asthma awakenings; and
number of severe exacerbations per patient per
year.
Cost and effectiveness assessments
The primary effectiveness variable in the economic
evaluation was the number of symptom-free days
(SFD) per year. The number of severe exacerbations
per patient per year was also measured. The SFD
has been recommended as an outcome measure in
guidelines for economic evaluation in asthma,12
and severe exacerbations have been related to
increases in cost.4
Utilisation of healthcare resources (e.g. days in
hospital, visits to a physician, etc.) and days on
which patients were unable to work (employment
or home-making) were recorded in case-report
forms. Medication use (study medication, reliever
medication, and other medication required after
the first severe exacerbation) was also recorded.
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The cost for each patient in the trial was estimated
by multiplying the resource use data by the cost per
unit for each type of resource, and adjusted for the
randomised period. Unit cost data were taken from
Swedish sources in 1999 prices and are shown in
Table 1.
ARTICLE IN PRESS
Table 1 Unit costs for healthcare resources, medications, and absence from work.




Visit to a physician Visit 1251 [13]
Visit to a nurse Visit 331 [14]
House-call by a nurse Call 341 [15]
House-call by a physician Call 859 [15]
Phone-call to a physician or nurse Call 56 [16]
Admission to hospital Day 3022 [13]
Pharmacy contact Contact 32 [17]
Study medication
Pulmicorts Turbuhalers 100 mg budesonide,
200 doses
Day (200 mg/day) 2.72 [18]
Pulmicorts Turbuhalers 200 mg budesonide,
200 doses
Day (400 mg/day) 4.00 [18]
Oxiss Turbuhalers 4.5 mg formoterol, 180
doses
Day (9 mg/day) 7.00 [18]
Reliever medication






Day (30mg/day) 4.98 [18]
Ventolins (maintenance) 200 mg salbutamol
pMDI, 100 doses
Day (8 inhalations/day) 4.32 [18]
Serevents (maintenance) 50 mg salmeterol,
180 doses
Day (2 inhalations/day) 7.70 [18]
Oxiss (maintenance) 9mg formoterol, 180
doses
Day (2 inhalations/day) 8.60 [18]
Becotide (maintenance) 0.2mg
beclomethasone, 120 doses
Day (2 inhalations/day) 3.05 [18]
Flutide (maintenance) 100 mg fluticasone, 180
doses
Day (2 inhalations/day) 5.12 [18]
Lomudal (maintenance) 20mg cromoglycate,
100 doses
Day (4 inhalations/day) 11.16 [18]
Theo-Dur (maintenance) 300mg theophylline,
100 tablets
Day (600mg/day) 3.01 [18]
Singulair (maintenance) 10mg montelukast, 49
tablets
Day (10mg/day) 11.76 [18]
Ventide (maintenance) Not available in
Sweden, so price
Day (2 inhalations/day) 4.13 [18]
estimated at Ventolin plus Becotide
Indirect costs
Absence from work Day Male 1434
Female 1181
[19]
Where data were taken from a source published prior to 1999, they were adjusted by inflation to 1999 prices.
pMDI¼pressurised metered dose inhaler.
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The cumulative costs and effectiveness during
the randomised period were estimated for each
patient individually and normalised to 1 year. This
differs slightly from the method used in the clinical
paper,3 where the clinical outcome variables were
calculated on a group basis for the randomised
period. It was important that both the cost and
effectiveness data in the economic evaluation were
estimated in the same way, and that costs and
effectiveness over a specific time period were
considered in the analysis. The clinical analysis was
based on exposure time, while the economic
analysis was based on individual data for the study
period of 12 months. If this approach is not used,
the economic analysis would be biased. Further-
more, a small number of patients did not provide a
complete set of economic resource use data and
were excluded from the economic analysis. For
these reasons, the effectiveness data in the
economic analysis differ slightly from those pre-
sented in the clinical paper.3
Cost–effectiveness
An incremental cost–effectiveness ratio (ICER)
compares one treatment group with another, by
taking the difference in cost between the two
groups and dividing it by the difference in effec-
tiveness between the two groups. This provides a
measure of the additional cost required to gain a
given unit of improvement in effectiveness.
In situations where there are more than two
treatments to compare, it is possible to rule out
any treatment that clearly has a less beneficial
cost–effectiveness profile than an alternative
treatment, i.e., at least one other treatment has
higher effectiveness and lower cost. In such a case
the treatment with the less beneficial profile is said
to be ‘dominated’ by the treatment(s) with higher
effectiveness and lower cost, and can be excluded
from further analysis.20 This simplifies the analysis
and reduces the number of comparisons needed.
The cost analysis was conducted from the
perspective of a healthcare payer (total healthcare
costs only) and from a societal perspective (health-
care costs and productivity costs). Incremental
cost–effectiveness ratios were calculated from a
societal perspective.
A sensitivity analysis was conducted by applying
unit costs (prices) from the UK and Spain to the
entire patient population. This did not significantly
change the overall results, and thus indicates that
the overall results are robust.
The study was not powered to detect differences
in cost; however observed differences in cost and
effectiveness were tested for statistical signifi-
cance using a parametric test.
Results
Clinical results
The clinical outcome results for the four treatment
groups are summarised in Table 2. All three step-up
treatments showed improvements compared with
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Table 2 Clinical outcomes results [3].








Patient numbers randomised 322 312 323 315
Change in FEV1 (% predicted) 0.27 0.90 2.55 4.13
Change in morning PEF (l/min) 2.78 1.73 12.89 18.50
Days with symptoms (%) 32.8 29.7 27.4 25.1
Number of reliever inhalations per day 0.89 0.75 0.66 0.63
Nights with awakenings (%) 6.0 6.0 5.4 4.5
Number of severe exacerbations per
year
0.92 0.96 0.56 0.36
Budesonide plus formoterol vs. budesonide alone P¼ 0.0001 for all parameters except nights with awakenings (nights with
awakenings P¼NS).
Budesonide 200mg vs. budesonide 100mg Po0.05 for change in FEV1, change in PEF and days with symptoms (other parameters
P¼NS).
Budesonide 100 mg plus formoterol 4.5 mg vs. budesonide 200mg alone Po0.05 for change in FEV1, Po0.01 for change in morning
PEF, Po0.001 for severe exacerbations per year (other parameters P¼NS).
FEV1¼ forced expiratory volume in 1 s; PEF¼peak expiratory flow.
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budesonide 100 mg alone. Budesonide 200 mg re-
duced the percentage of days with symptoms
compared with budesonide 100 mg (Table 2). Bude-
sonide 100 mg plus formoterol 4.5 mg was signifi-
cantly more effective than budesonide 200 mg alone
in reducing the risk of a severe exacerbation or a
poorly controlled asthma day3 and in improving
FEV1, morning PEF and the number of severe
exacerbations per year (Table 2). The magnitude
of the improvement with budesonide 200 mg plus
formoterol 4.5 mg was larger than that seen with
budesonide 100 mg plus formoterol 4.5 mg in all
parameters, although these differences were not
tested for statistical significance3 (Table 2). Thus,
clinical efficacy increased in the order: budesonide
100 mg alone, budesonide 200 mg alone, budesonide
100 mg plus formoterol 4.5 mg, budesonide 200 mg
plus formoterol 4.5 mg.
Economic results
The results for the outcome measures used in the
economic evaluation are shown in Table 3. As
described in the Methods section, these data differ
slightly from the clinical outcomes data shown in
Table 2. The overall pattern of improvement was
similar to that seen with the clinical outcomes
data; budesonide 200 mg plus formoterol 4.5 mg was
the most effective, followed by budesonide 100 mg
plus formoterol 4.5 mg, followed by budesonide
200 mg alone. Patients receiving budesonide 200 mg
plus formoterol 4.5 mg experienced the largest
number of SFD per year, and the fewest severe
exacerbations per year.
The use of resources by each group is shown in
Table 4. The healthcare costs for each group are
shown in Table 5 and Fig. 1. As would be expected,
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Table 3 Mean values (standard deviation) for the effectiveness variables used in the economic analysis.
Variable Budesonide Budesonide Budesonide 100 mg plus Budesonide 200 mg plus
100 mg alone 200 mg alone formoterol 4.5 mg formoterol 4.5mg
Patient numbers 313 302 310 308
SFD (%) 68.95 72.54 74.04n 75.19nn
(32.65) (31.12) (30.36) (29.36)
Number of SFD per year 252 265 270 275
Number of severe 0.89 0.92 0.64nnn 0.35w
exacerbations per year (2.23) (3.08) (2.27) (0.99)
Tests conducted to compare the step-up alternatives with formoterol to the step-up alternative with budesonide alone.
SFD¼ symptom-free days.
nP¼ 0.55 vs. budesonide 200mg alone.
nnP¼ 0.28 vs. budesonide 200mg alone.
nnnP¼ 0.021 vs. budesonide 200 mg alone.
wP¼ 0.002 vs. budesonide 200 mg alone.
Table 4 Resource use in the four treatment groups.
Resource Budesonide Budesonide Budesonide 100 mg Budesonide 200 mg
100 mg alone 200 mg alone plus formoterol 4.5 mg plus formoterol 4.5 mg
Patient numbers 313 302 310 308
Number of treatment days 104,752 103,684 104,748 104,265
Patients hospitalised 4 5 1 4
Number of days in hospital 60 63 8 9
Number of visits to a physician 191 149 151 165
Number of visits to a nurse 7 2 0 4
Number of house-calls by a physician 12 3 5 6
Number of house-calls by a nurse 1 0 0 0
Number of phone-calls 91 51 63 51
Number of pharmacy contacts 61 37 49 49
Patients with missed workdays 38 37 24 33
Number of missed workdays 303 402 137 171
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all three step-up treatments were associated with
increased study-medication costs compared with
budesonide 100 mg alone. However, the patients
receiving budesonide 100 mg plus formoterol 4.5 mg
or budesonide 200 mg plus formoterol 4.5 mg re-
quired substantially fewer days in hospital than
either of the budesonide-only groups (Table 4),
resulting in a reduction in the costs of healthcare
resources (Table 5; Fig. 1). This, combined with
reductions in the costs of reliever and other
medications, partly offset the additional cost of
formoterol. Increasing the dose of budesonide
without adding formoterol was associated with a
smaller increase in study-medication costs, but
without the offsetting reduction in hospital days or
healthcare resources seen in the formoterol groups.
The number of days missed from work was also
substantially reduced in patients receiving either
budesonide 100 mg plus formoterol 4.5 mg or bude-
sonide 200 mg plus formoterol 4.5 mg (Table 4). The
reduction in time off work has an intrinsic value in
itself in reduced disruption to patients’ lives. A
monetary value for time off work (productivity
cost) can also be estimated, and is shown in Table 5
and Fig. 1. The substantial savings in productivity















































Fig. 1 Costs (SEK per patient per year) in the four treatment groups.













Study medication 993 1461 3550 4018
Reliever medication 246 205 188 159n
Other medication 233 249 159 157
Healthcare resource costs 1493 1644 815 817
Total healthcare costs 2965 3559 4712nn 5151nnn
Productivity costs 1390 2109 1180 718w
Total costs 4355 5668 5893 5868
Tests conducted to compare the step-up alternatives with formoterol to the step-up alternative with budesonide alone.
No P-values calculated for study-medication cost, as this was driven by the study protocol; no statistically significant differences
in total costs between any of the groups; totals may not add due to rounding.
nP¼ 0.045 vs. budesonide 200mg alone.
nnP¼ 0.045 vs. budesonide 200mg alone.
nnnP¼ 0.006 vs. budesonide 200 mg alone.
wP¼ 0.04 vs. budesonide 200 mg alone.
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the reduction in the number of days off work,
almost completely offset the additional cost of
formoterol compared with budesonide 200 mg (Ta-
ble 5). When the savings in productivity costs were
included (taking a societal perspective), there
were no statistically significant differences in total
costs between any of the treatment groups, and
the three step-up treatment groups were numeri-
cally almost identical (Table 5; Fig. 1).
Cost–effectiveness
Comparing the three step-up treatments, budeso-
nide 100 mg plus formoterol 4.5 mg had the highest
total cost (Table 5). However, it was not the most
effective treatment, as budesonide 200 mg plus
formoterol 4.5 mg provided more SFD per year
(Table 3). Therefore, since budesonide 100 mg plus
formoterol 4.5 mg was both more expensive and less
effective than budesonide 200 mg plus formoterol
4.5 mg, it clearly could not provide the best ‘value
for money’. In this situation, budesonide 100 mg
plus formoterol 4.5 mg is said to be ‘dominated’,
and was excluded from the analysis.
This left budesonide 200 mg alone to be compared
with budesonide 200 mg plus formoterol 4.5 mg in
the cost–effectiveness analysis. Budesonide 200 mg
plus formoterol 4.5 mg provided more SFD per year
(Table 3) but was associated with higher costs
(Table 5), i.e., it was both more effective and more
expensive than budesonide 200 mg alone. The ICER
for this comparison was SEK 21 per SFD gained.
Discussion
International guidelines recommend a stepwise
approach to asthma treatment, increasing control-
ler therapy until optimal control of asthma is
achieved.1 The present study provides data on the
economic effects of three potential options for
stepping up treatment. The study patients would
be candidates for step-up therapy, as they had to
show signs of sub-optimal control during the run-in
period of treatment with budesonide 100 mg twice
daily. The results show that treatment with
formoterol plus budesonide improved asthma con-
trol, and was more effective than doubling the
corticosteroid dose in improving FEV1, improving
PEF and reducing the number of severe exacerba-
tions per year 3 (Table 2). Adding formoterol 4.5 mg
to either dose of budesonide significantly increased
the time until the first severe exacerbation,
reduced the number of days with poorly controlled
asthma symptoms, reduced the need for reliever
medication and improved lung function (FEV1 and
PEF).3 These results show that even patients with
mild asthma can obtain significant clinical benefit
by stepping up therapy from a low dose of inhaled
corticosteroids alone, and are consistent with the
earlier findings of clinical benefit obtained by
adding formoterol to budesonide treatment in
patients with moderate asthma.10
The effectiveness measures used in the economic
analysis showed a similar pattern. Budesonide
200 mg plus formoterol 4.5 mg provided the largest
number of SFD per year, and the greatest reduction
in the number of severe exacerbations per year
(Table 3).
These clinical benefits were obtained at a modest
additional cost. Combination treatment with bude-
sonide and formoterol was associated with reduc-
tions in the costs of reliever medication, other
medications and healthcare resources (such as
hospitalisation and visits to healthcare profes-
sionals), at either dose of budesonide, and these
savings offset most of the additional cost of
formoterol treatment. When productivity costs
were also included, there were no significant
differences in total costs between any of the
treatment groups.
Budesonide 100 mg plus formoterol 4.5 mg was
associated with the highest total cost, but was not
the most effective treatment. The reason that the
costs were higher for 100 mg plus formoterol 4.5 mg
than for budesonide 200 mg plus formoterol 4.5 mg
was basically the lower productivity costs in the
latter group (likely to result from the higher
efficacy in that group). Since budesonide 200 mg
plus formoterol 4.5 mg was both more effective and
less expensive, budesonide 100 mg plus formoterol
4.5 mg was excluded from the analysis, leaving
budesonide 200 mg plus formoterol 4.5 mg to be
compared with budesonide 200 mg alone. Budeso-
nide 200 mg plus formoterol 4.5 mg was both more
effective and more expensive than budesonide
200 mg alone. The difference in costs was modest.
Taking the societal perspective, the net increase in
total costs was SEK 200 per patient per year, or SEK
0.55 (equivalent to Euros 0.06 at the November
2002 exchange rate [Euro 1¼ SEK 9.0181]) per
patient per day, for budesonide 200 mg plus
formoterol 4.5 mg compared with budesonide
200 mg alone. Each additional SFD gained by using
budesonide 200 mg plus formoterol 4.5 mg instead of
budesonide 200 mg alone cost SEK 21 (Euros 2.32).
For comparison, a study using economic model-
ling techniques calculated that using inhaled
corticosteroid treatment in patients with mild-to-
moderate persistent asthma cost US$ 7.50 per
SFD gained, compared with using rapid relief
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medication alone.25 This is equivalent to SEK 67 at
the November 2002 exchange rate of US$ 1¼ SEK
8.99. Our finding of SEK 21 per SFD in the present
study thus compares favourably with Paltiel et al.21
although direct comparisons between studies with
differing methodology should be made with cau-
tion.
The SFD measure is asthma-specific and thus
cannot be used to make economic comparisons
between treatments for asthma and treatments for
other diseases. Such comparisons would require
data using a general outcome measure, such as
quality-adjusted life-years (QALYs).
The reductions in days in hospital and days off
work observed in the patients receiving formoterol
and budesonide have an intrinsic value, as well as
their monetary value. Hospitalisation is disruptive
and may also be distressing or frightening for
patients and their families. Time lost from work
or education may impair future career prospects.
The adverse impact of asthma, especially poorly
controlled asthma, on patients’ lives may be
considerable. For example, in a population-based
survey conducted in the USA, 22% of patients with
poorly controlled asthma felt that their disease had
interfered with their career plans, and 44% felt that
it interfered with their social lives.22 Outcomes
such as these are not generally captured by
conventional measures of clinical status, and
cannot be inferred from them,23 but are clearly
of importance to patients. Improved asthma con-
trol provides important intangible benefits by
allowing patients to lead fuller lives with less
disruption due to asthma symptoms. For example,
in the US survey mentioned above, the percentages
of patients with controlled asthma who said the
disease interfered with their career plans or social
lives were 10% and 5%, respectively, significantly
lower than in the patients with poorly controlled
asthma.22 The improvements in asthma control
(more SFD per year, fewer severe exacerbations per
year) observed in the patients taking combined
formoterol and budesonide in the present study are
likely to represent valuable intangible benefits, but
these benefits were not quantified.
When conducting an economic evaluation based
on a multinational clinical study, at least two
difficulties exist: (1) healthcare utilisation and
treatment patterns differ between countries, and
(2) unit costs (prices) differ.24,25 Selecting the
patients from one individual country is often not
feasible due to the power of the study. Thus, data is
most often pooled across all countries and are then
multiplied with the unit costs from one country.
Pooling data is an area of current health economic
research, since variations in healthcare systems
and treatment patterns may influence the policy
implications for individual countries based on the
overall results. There exist some statistical techni-
ques for how to deal with this variability, but a
preferred approach does not yet exist, and these
complex issues were beyond the scope of the
present study.26 For this economic analysis, we
chose to use Swedish unit cost data because the
information is readily available, health economic
data is of great interest in healthcare decision-
making in Sweden, and because Sweden contrib-
uted with many patients in this study. Clearly, some
caution should be exercised when applying these
results to other countries (especially if there is a
great difference in unit cost structure).
The results of the present study are consistent
with those reported by an economic analysis of
data from a clinical trial in patients with moderate
asthma.11 In that study, the addition of formoterol
to budesonide improved effectiveness, reduced
total costs in Sweden, and was clearly cost-
effective.11 This result, derived from the clinical
study by Pauwels et al.10 was unexpected at the
time and has influenced treatment guidelines and
healthcare policy. Formoterol combined with an
inhaled corticosteroid is now an established com-
ponent of therapy for patients with moderate
asthma.1 The present study and the clinical trial
on which it is based 3 have shown that the benefits
of combined budesonide and formoterol treatment
can also be extended to patients with milder
persistent asthma.
In summary, combined treatment with budeso-
nide 200 mg and formoterol 4.5 mg in patients with
mild-to-moderate persistent asthma improved
asthma control compared with budesonide 200 mg
alone at a modest increase in cost, and the cost–
effectiveness of treatment compared favourably
with results reported in other studies. These
findings indicate that budesonide and formoterol
could provide a cost–effective treatment option in
patients with mild-to-moderate persistent asthma
who would benefit from stepping-up treatment.
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